IMAX recent weakness a buying opportunity, says JPMorgan JPMorgan views the year-to-date pullback in shares of IMAX as a buying opportunity. The firm believes IMAX is performing well in China while the stock represents the best way to play the "promising" 2015 box office. JPMorgan keeps an Overweight rating on IMAX with a $32 price target.
News For IMAX From The Last 14 Days
Check below for free stories on IMAX the last two weeks.